- I recommended AbCellera on March 8, 2021, and so far the stock has gone pretty much nowhere. However, I am as bullish as ever.
- Immediate catalysts are lacking, but that does not preclude you from accumulating this stock at a reasonable valuation before the fireworks start.
- Long term, this company should be worth many multiples of the current price and my strategy is simply to accumulate as much as I can under $30.
- Patience is needed as non-COVID-19 royalties are still many years away. Once royalties begin in earnest, however, the time to buy will have been long gone.
For further details see:
AbCellera Biologics: My Highest Conviction Pick, With The Longest Potential Payoff